Pfizer offers Pfizer Oncology Together, a patient support program to help patients access their prescribed Pfizer Oncology medications, identify financial assistance options, and connect patients to a dedicated Care Champion. A complete list of Pfizer Oncology medications and their related assistance programs is provided in the Table.
Pfizer Oncology Together
Pfizer Oncology Together offers the Pfizer Oncology Together Co-Pay Savings Program, the Pfizer Patient Assistance Program, and the Care Champion Program.
Pfizer Oncology Together Co-Pay Savings Program
Co-pay savings are available for eligible, commercially insured patients who are prescribed certain Pfizer Oncology oral or injectable medications. Limits, terms, and conditions apply depending on the medication prescribed. To learn more or to enroll your patient in Pfizer Oncology Together Co-Pay Savings Program, please visit the Pfizer Oncology Together Co-Pay Savings Program or call 877-744-5675.
Pfizer Patient Assistance Program
Through the Pfizer Patient Assistance Program, uninsured patients may receive free medication for up to 1 calendar year, while underinsured patients are enrolled through the end of the calendar year. To be evaluated for assistance through this program, you and your patient must each submit a completed enrollment form. Patients must also provide proof of income, such as the prior year’s tax return, a W-2 form, or paycheck stub.
The Care Champion Program is a free patient support program for patients prescribed a Pfizer Oncology medication. Patients are partnered with a dedicated Care Champion who has social work experience and can provide resources that may help with some of their daily challenges, no matter where they are in the treatment journey. To learn more or to enroll your patient in the Care Champion Program, please visit www.pfizeroncologytogether.com/hcp/patient-support#care-champion-program.
Adjuvant treatment of postmenopausal women with estrogen receptor–positive early breast cancer who have received 2 to 3 years of tamoxifen and are switched to Aromasin for completion of 5 consecutive years total of adjuvant hormonal therapy; treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy
Treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome–positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy; adult patients with accelerated or blast phase Ph+ CML with resistance or intolerance to prior therapy
Treatment, in combination with binimetinib, of patients with unresectable or metastatic melanoma and a BRAF V600E or V600K mutation, as detected by an FDA-approved test; treatment, in combination with cetuximab, of adults with metastatic colorectal cancer and a BRAF V600E mutation, as detected by an FDA-approved test, after previous therapy; treatment, in combination with binimetinib, of adult patients with metastatic non–small cell lung cancer with a BRAF V600E mutation, as detected by an FDA-approved test
First-line therapy, in combination with 5-fluorouracil and leucovorin, for patients with metastatic carcinoma of the colon or rectum; treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy
Treatment of adult patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer in combination with either an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant in patients with disease progression following endocrine therapy
In combination with avelumab, for the first-line treatment of advanced renal cell carcinoma (RCC); in combination with pembrolizumab, for the first-line treatment of advanced RCC; as a single agent, for the treatment of advanced RCC after failure of 1 prior systemic therapy
Treatment, in combination with encorafenib, of patients with unresectable or metastatic melanoma and a BRAF V600E or V600K mutation, as detected by an FDA-approved test; treatment, in combination with encorafenib, of adult patients with metastatic non–small cell lung cancer with a BRAF V600E mutation, as detected by an FDA-approved testt
Treatment of newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older; treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia
Treatment of adult patients with gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate; treatment of adult patients with advanced renal cell carcinoma (RCC); adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy; treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in adult patients with unresectable locally advanced or metastatic disease
As a single-agent treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative, locally advanced or metastatic breast cancer, based on an FDA-approved companion diagnostic; in combination with enzalutamide for the treatment of adult patients with HRR-mutated, metastatic castration-resistant prostate cancer
Treatment of HER2-overexpressing breast cancer; treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Select patients for therapy based on an FDA-approved companion diagnostic
Treatment of patients with metastatic non–small cell lung cancer whose tumors are ALK- or ROS1-positive, as detected by an FDA-approved test; pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large-cell lymphoma that is ALK-positive; adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor that is ALK-positive
First- or second-line treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy; second-line treatment of metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who have progressed on a first-line bevacizumab regimen
To decrease the incidence of infection (as manifested by febrile neutropenia) in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever; reduce time to neutrophil recovery and duration of fever after chemotherapy in patients with acute myeloid leukemia; to reduce duration of neutropenia and neutropenia-related sequelae in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplant; for mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis; to reduce incidence/duration of severe neutropenia sequelae in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia
Ruxience (rituximab-pvvr) injection Indications
Treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin lymphoma (NHL) as a single agent; previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; nonprogressing, low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone chemotherapy; previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, prednisone, or other anthracycline-based chemotherapy regimens; in combination with fludarabine and cyclophosphamide, for the treatment of adult patients with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia